Legend Biotech Corp.

As Chinese biotech companies have faced a cash crunch at home, it has become necessary for them to look abroad for partnering opportunities to advance their assets through the clinic. This trend has l

Once almost written-off, GSK ’s Blenrep now looks like a practice-changing therapy for patients with relapsed/refractory multiple myeloma, after the company unveiled impressive Phase III overall surv

The data that Gilead Sciences subsidiary Kite and Arcellx presented at the American Society of Hematology meeting for anitocabtagene autoleucel (anito-cel) were positive, but the question that remains

The dizzying array of new treatments for multiple myeloma is set to become even more complex in the near future, and a new platform trial aims to get a better handle on how the variety of drugs with d